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occurred at a rate of 60%, 63%, 67%, 70%, and 90% in AL100, AL20, AL500,
HA, and NS, respectively.
Histology. In the NS group, loss of the superﬁcial layer, ﬁbrillation, and cleft
were observed. In the HA and the AL500 groups, cartilage degeneration
including ﬁbrillation, ﬁssures, and loss of proteoglycan was observed in the
femoral condyle. An obvious reduction in the severity was found in the
AL100 group. The overall degenerative score of the AL100 group tended to
be the lowest, indicating that AL100 suppressed degradation. The overall
scores of the treatment groups were signiﬁcantly lower than that of the NS
group (AL20, AL100, and AL500 vs NS, p<0.01; HA vs NS, p<0.05).
Friction. The friction coeﬃcients of the AL100 and the AL20 group were
signiﬁcantly lower than that of the NS and the HA group (P<0.05).
Table 1. Histological scores and friction coeﬃcient
Histological score Friction coeﬃcient
NS 21.3±1.3 0.0294±0.0014
HA 17.3±1.2 0.0235±0.0013
AL20 14.9±0.9 0.0148±0.0027
AL100 12.6±0.9 0.0122±0.0037
AL500 15.4±0.9 0.0232±0.0117
Conclusions: The current study is the ﬁrst to examine the inﬂuence of
alginate materials on OA progression in vivo. Our ﬁndings suggest that
intraarticular administration of the UPLE-alginates is effective in prevent-
ing articular cartilage degeneration and on improving joint lubrication of
OA knees induced by ACLT. In terms of molecular weight dependency,
AL100 (1.0×106 Da) has more therapeutic effects on OA progression.
Based on these results, we reasonably conclude that the UPLE-alginates,
especially AL100, have promising potential for becoming an effective agent
of intraarticular injection for preventing OA progression.
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EFFECTS OF INTRA-ARTICULAR INJECTIONS OF HYLAN GF-20 ON SERUM
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THE BIOVISCO STUDY
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Purpose: Viscosupplementation (VS) by intra articular (IA) injection of
hyaluronic acid (HA) is widely used to reduce pain in patients with
knee osteoarthritis (K-OA). However little is known on its effect on joint
metabolism as well as on its possible structure modifying effect. Objectives:
To investigate the effect of VS on circulating OA biomarkers in patients
with K-OA.
Methods: Prospective open label study. 51 patients with unilateral symp-
tomatic K-OA (ACR criteria; Kellgren-Lawrence grade I to IV) received an
IA injection of 2mL of HA (hylan GF-20) IA injection on days (D) 1, 7, 14
and were followed 3 months. At D-15 patients were examined and X-rays
were performed, in order to exclude patients with bilateral K-OA, or those
with more than 3 OA joints including the target knee. From D-15 to D90
concomitant therapies were unchanged. Walking pain (WP) on VAS was
obtained at each visit. Clinical response was deﬁned as a WP decrease >30
mm between D1 and D90 (50% improvement). Urine (U) and serum (S)
samples were obtained, using a standardized procedure, 2 weeks before
the ﬁrst injection (D-15), then at D1 (1st injection), D30 and D90. S-C2C,
S-Cartilage oligomeric protein (S-COMP), S-HA, S-CS846 epitope, S-type II
collagen propeptide (S-PIICP) and U-type II collagen C telopeptide (CTX
II/creatinin) were assayed. Variations over time for each biomarker were
studied using Wilcoxon rank sum test.
Results: 45 patients (mean age 57.7, mean BMI 26.7) were analyzed. At
baseline there was no difference between ITT and per-protocol population.
Between D-15 and D1 there was no signiﬁcant difference for any biomark-
ers (all p>0.05), indicating a good reproducibility in S and U measurements
and the absence of spontaneous variation over time. At D1 WP was
correlated with U-CTX II/creat (p=0.006). Between D1 and D90: Mean (SD)
WP decreased from 57.7 (15.4) to 29.3(22.9) mm (p<0.0001). No variation
was found for any S-biomarker. By contrast U-CTX II/creat was reduced
by 20.5% and decreased signiﬁcantly between D1 and D90 (385.1 vs 306.0
ng/mmol creat; p= 0.02). Furthermore U-CTX II and S-HA levels at baseline
were both but independently predictive of clinical response to treatment
(p=0.03 and p=0.02) even after adjustment for age, gender and BMI. Further
more in logistic regression including age, BMI, bilaterality, KL grade, OA at
other joints, DMOADS consumption and U-CTX II/creat at baseline, there
was a signiﬁcant correlation between clinical response and U-CTX II/creat
level variation (p=0.03).
Conclusions: This study suggests that hylan IA injections are able to mod-
ify the knee joint metabolism in patients with OA resulting in a decrease
in urine CTX II concentrations, particularly in patients with the highest
levels of U-CTX II and HA before treatment. Further studies coupling
biomarkers and imaging techniques are needed to investigate the possible
chondroprotective effect of hylan in K-OA.
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Purpose: VEGF is both a potent angiogenic and vascular permeability factor
that is crucial in endochondral ossiﬁcation involved in bone formation and
remodeling. We hypothesize that osteoarthritis (OA) pain-associated bone
marrow lesions, effusion, and synovitis are in part, driven by VEGF medi-
ated increases in vascular permeability. Soluble fms-link tyrosine kinase 1
(sFlt1), a variant of VEGF receptor Flt1, can potentially block the function of
VEGF. Our previous work demonstrated that VEGF inhibition using virally
delivered sFlt decreased synovitis and pain marker expression in a rabbit
OA model. However, the biological joint half life of recombinant human
sFlt01, a VEGF neutralizing Fc fusion protein, was demonstrated to be just
a few hours. In order to prolong the joint half life of sFlt01, we constructed
a modiﬁed delivery form of this protein, veriﬁed its bioactivity, and con-
ﬁrmed enhanced stability compared to sFlt01 in accelerated stability tests
up to 3 months.
Methods: Modiﬁed sFlt delivery construct TCEP reduction and CuCl2 ox-
idation were used to create a dimerized modiﬁed sFlt delivery construct,
which was subsequently column puriﬁed and compared to native sFlt as
well as the monomer forms of the modiﬁed delivery construct on silver
stained SDS PAGE gels.
In vitro VEGF ELISA binding assay A two-fold serial dilution of sFlt01 or
the modiﬁed sFlt delivery construct starting from 10,000 pM was made
in assay medium (M199 media + 5% FBS + 1x Penn/Strep). VEGF165 (10
pM) was then incubated with the serial dilutions. Unbound VEGF for each
dilution was measured by ELISA to identify whether any shift had occurred
between VEGF neutralization by the modiﬁed sFlt delivery construct vs.
native sFlt01 control.
Accelerated stability test Modiﬁed sFlt delivery construct (0.25 mg/ml)
was incubated in PBS with 1X HALT protease inhibitor cocktail with EDTA
(Pierce) at 45°C and aliquots drawn and ﬂash frozen at -80°C. Unmodiﬁed
sFlt01 at the same concentration was used as a control. The samples were
collected over different time points in both 36 and 94 day stability tests.
The samples with or without PNGase F treatment was further analyzed by
silver-stained reducing SDS PAGE.
Results: TCEP reduction and CuCl2 oxidation resulted in successful dimer-
ization of the modiﬁed sFlt delivery construct.
TCEP reduced protein monomer showed ∼35 fold higher EC50 vs. native
sFlt01 whereas Cu2+ oxidized dimer showed 2.2 - fold high EC50 compared
to sFlt01.
From the accelerated stability test data, sFlt01 control showed increase
amount of ∼35 kDa product as well as high molecular weight of ∼115
kDa product in silver stained reducing SDS PAGE without PNGase treat-
ment. The modiﬁed sFlt delivery construct showed greater stability at
elevated temperature, generating less high molecular weight aggregate and
fragmentation compared to sFlt01 control at both 36 and 96 days.
Conclusion: The generated modiﬁed sFlt delivery construct expressed from
HEK293 can be eﬃciently dimerized.
Copper-generated protein dimer retains high aﬃnity for VEGF binding,
comparable to native sFlt01.
The modiﬁed sFlt delivery construct appears more stable at elevated tem-
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perature vs. sFlt01, suggesting a sustained release formulation is possible
without fragmentation.
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ACCURACY OF INTRA-ARTICULAR INJECTIONS IN THE KNEE:
A SYSTEMATIC REVIEW
J. Hermans
Erasmus MC Univ. Med. Ctr., Rotterdam, Netherlands
Purpose: Intra-articular injections in the knee joint are commonly used for
therapeutic and diagnostic goals concerning knee pathology. Several ap-
proaches are used to establish an intra-articular injection in the knee joint,
however accuracy rates differ per approach. The primary objective was to
summarize the evidence concerning the accuracy of different approaches
for intra-articular injections in the knee.
Methods: The literature was systemically reviewed in online databases
Pubmed and Embase until June 2009. Two reviewers (JH, MR) indepen-
dently applied the inclusion and exclusion criteria and inclusion was
reached by consensus. Risk of bias of the included studies was assessed
independently by 2 reviewers using the QUADAS-tool. Study characteris-
tics, accuracy data, other outcome measures, results and conclusions were
independently extracted by 2 reviewers. A trained statistician pooled the
accuracy rates per used injection approach.
Results: In total, 9 studies were included. The superolateral approach with
the knee in extension was studied most (230 injections) and resulted in the
highest pooled accuracy of 89% (95% C.I. 85%-93%). Pooling of the medial
midpatellar approach, the anterolateral approach and the anteromedial
approach resulted in the lowest pooled accuracy rates, respectively in 56%
(95% C.I. 46%-68%), 70% (95% C.I. 64%-77%) and 71% (95% C.I. 65%-78%).
Conclusion: Based on the results of this systematic review the authors
recommend the superolateral approach with the knee in extension for the
intra-articular injection of the knee joint.
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CLINICAL RESULTS OF OPENWEDGE HIGH TIBIAL OSTEOTOMY FOR
OSTEOARTHRITIS AND OSTEONECROSIS OF THE KNEE
R. Takeuchi1 , H. Ishikawa1, K. Kumagai1, Y. Yamaguchi1, T. Fuzisawa1,
T. Kuniya1, Y. Akamatsu1, A. Nakazawa2, T. Saito1
1Yokohama City Univ. Sch. of Med., Yokohama, Japan; 2Yokohama munincipal
Hosp., Yokohama, Japan
Purpose: We performed clinical and radiographic evaluation of patients
with medial compartmental osteoarthritis and spontaneous osteonecrosis
of the knee who had undergone treatment with opening-wedge high
tibial osteotomy (OWHTO) followed by early full weight bearing. OWHTO
procedure were performed using TomoFix™ and bone substitute materials.
Methods: OWHTO was performed in 93 knees of 77 patients of an average
age of 68 years (range 52-82) at the time of the operation. Sixty-three
knees from 47 patients were diagnosed as primary osteoarthritis (OA)
and a further 30 patients were diagnosed as spontaneous osteonecrosis
(ON). We established an early weight bearing program during which these
patients were permitted partial weight bearing exercise one week after
their osteotomy. Patients who performed OWHTO for one side started full
weight bearing walk at two weeks, and patients simultaneous bilateral
cases (11 patients) started full weight bearing at three weeks post-surgery.
The average follow-up period was 49 months (range 24 to 83 months).
Clinical examinations of the knee joints in our patient cohort consisted of
both subjective and objective parameters that were recorded and docu-
mented using the American Knee Society Knee Score (KSS) and Function
Score. These evaluations were carried out presurgically and at the time of
follow-up. Additional clinical ﬁndings that were assessed included range
of motion, Japanese-style sitting, and possible post-surgical complications.
Radiological evaluations were carried out on the femoro-tibial angle (FTA),
using an AP weight bearing radiograph of a single leg, with the knee joint in
extension. A weight bearing line (WBL) ratio was calculated using standing
long-cassette radiographs of the lower extremities.
Results: Functional assays, including the American Knee Society Score and
Function Score, showed signiﬁcant improvement from 49±11 to 91±7.7
points, and 62±13 to 95±8.2 points, respectively. Prior to surgery, the
average femoro-tibial angle during standing was 181±2.5° (1° anatomical
varus) but measured 169±2.2° (11° valgus) at the time of follow-up. There
were no instances of non-union or implant failure in any of our patient
subjects. Furthermore, 54 of the patients in our study group (70%) could
sit comfortably in the Japanese style after surgery. Their average FTA was
181.3±2.4°(11° varus) and average WBL ratio was 17.2±16.5%, indicating
that the WBL had shifted toward the medial compartment. After surgery,
the FTA improved to 169.6±2.3° (10° valgus) and the WBL ratio shifted
to 62.9±12.5%, indicating that the WBL had moved toward the lateral
compartment of the knee.
Conclusions: We demonstrate that an early weight bearing exercise pro-
gram enables full weight bearing at two weeks after OWHTO with TomoFix
and artiﬁcial bone wedges. Overall, this combination was a highly success-
fully course of treatment for correcting knee malalignment in patients with
medial compartmental OA and ON of the knee.
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Purpose: To investigate the eﬃcacy and safety of a three intra-articular
injection course with Jointex Mini (Hyaluronic Acid 8mg/1ml, Chiesi Far-
maceutici S.p.A., Parma, Italy) for the treatment of symptomatic OA of the
CMC.
Methods: Fourty-eight female patients affected by symptomatic CMC OA
(age 51-90 years; 67±9 years, mean ± SD) were treated with three
once-weekly intra-articular injections of Jointex Mini. All subjects met ACR
criteria for hand OA and had CMC OA grade 1-4 according to Kellgren
and Lawrence on standard X-ray performed within 6 months before the
inclusion. Twelve patients showed bilateral OA so that globally 60 CMC
joints were treated. Patients were followed for
a 3-month period after the last injection. Treatment eﬃcacy was assessed
through visual analogue scale (VAS) pain quantiﬁcation (baseline; 2nd and
3rd injection; one and three months after the last injection). Side effects
were recorded.
Results: VAS was signiﬁcantly reduced after the ﬁrst injection (2nd injec-
tion vs baseline, p<0.005; 3rd injection vs baseline, p<0.0001; 3rd injection
vs 2nd injection, p<0.05) and reached the slowest score one month after
the last injection. The eﬃcacy was maintained for all the 3-month follow-
up period (one month vs baseline, p<0.0001; three months vs baseline,
p<0.0001; - one month vs 3rd injection, p=n.s.; three months vs 3rd
injection, p=n.s.). Only minor side effects were observed (mild pain and/or
ecchymosis in injection site).
Conclusions: Our study supports viscosupplementation with Jointex Mini
as a safe and eﬃcacious approach for symptomatic CMC OA. Our schedule
based on three weekly intra-articular injections supplies pain relief lasting
as long as 3 months with negligible side-effects.
